U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07620730) titled 'PrEP-LANA (Pre-exposure Prophylaxis- Long-acting Novel Antiviral Agent)' on May 20.
Brief Summary: The goal of this 12-month implementation science study is to generate the evidence required to ensure long-acting cabotegravir (LA CAB) as pre-exposure prophylaxis (PrEP) can be delivered in an equitable manner within the NHS. This study will recruit both PrEP users and healthcare professionals (HCPs).
The main questions it aims to answer are:
* What do healthcare providers think about the feasibility of delivering LA CAB PrEP within sexual health services in the NHS?
* How many participants stay on/remain consistent with LA CAB PrEP...